E Fund Biopharma(03186.HK) up 1.47%, China out-licensing tops $120bn

NewTimeSpace News: Faster out-licensing of Chinese innovative drugs and a raft of industrial policy measures lifted Hong Kong-listed healthcare names. As of 10:47 on September 23, 2026, the E Fund (HK) Solactive Biopharma Select Index ETF(03186.HK) rose 1.47% intraday, quoted at HK$15.150, with turnover of HK$958,500, volume of 63,400 units and a turnover rate of 3.73%.

NewTimeSpace understands that the ETF, managed by E Fund Asset Management (Hong Kong), tracks the Solactive Biopharma Select Index and covers biopharma companies listed in Hong Kong and the United States; it is the world's first biopharma-themed ETF covering both markets. As of 10:47 HKT on September 23, 2026, it had assets of HK$25.4066 million, a net asset value of HK$14.945 per unit and a board lot of 100 units.

On the news front, People's Daily reported that out-licensing deals by Chinese innovative drug makers have exceeded US$120 billion so far this year, up 36% year on year, with upfront payments topping US$10 billion. Separately, the 15th Five-Year Plan for the pharmaceutical industry issued by the Ministry of Industry and Information Technology and other departments targets average annual growth of more than 20% for the innovative drug industry by 2030, with first-in-class drugs accounting for more than 25% of the global total.

Northeast Securities said in a research note that favourable industrial policies and a wave of AI drug discovery catalysts are helping Chinese innovative drug makers gain overseas recognition for their R&D strength.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.